关于癌症结果和相关的DNA微阵列的预测能力:经验评估
Evangelia E Ntzani1, John P A Ioannidis
1Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Lancet (London, England)
|November 7, 2003
概括
DNA微阵列显示了癌症结局的可变预后性能. 对于这种有前途的技术,有适当的验证和临床设计的大型研究是必不可少的.
科学领域:
- 基因组学就是基因组学.
- 在瘤学瘤学.
- 生物统计学 生物统计学
背景情况:
- DNA微阵列可以同时分析成千上万个基因,用于诸如癌症预测等应用.
- 基因表达分析越来越多地用于预测临床结果,如死亡,转移,复发和对治疗的反应.
研究的目的:
- 系统地评估DNA微阵列对主要癌症临床结果的预测性能.
- 评估基因分析与恶性疾病的其他临床病理相关的相关性之间的相关性.
主要方法:
- 对MEDLINE (1995-2003) 资格报告进行了系统审查.
- 研究评估了设计特征,报告了预测性表现,并考虑了预后因素.
- 确定了增加重大关联可能性的变量.
主要成果:
- 确定了84项符合条件的研究,30项专注于主要临床结果,中位数为25名患者.
- 较小的研究显示出比较大的研究更好的灵敏度和特异性.
- 显著的关联更有可能与增加的样本大小和微阵列探针,但验证往往是不完整的.
结论:
- DNA微阵列在癌症结局预测中显示出可变的预后性能.
- 结合适当的临床设计,对已知的预测因子进行调整和严格验证的更大规模研究至关重要.
- 需要进一步的研究来优化这种技术的使用,以便可靠地预测癌症.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
